Changes in lipid metabolism of resistant to BRAF/MEK inhibitors human melanoma cells associated with the presence of adipocytes within tumor niche
2020/39/D/NZ5/02330
Keywords
Descriptors
- NZ5_003: Patogeneza chorób człowieka
- NZ5_007: Leczenie chorób człowieka
Panel
NZ5 – Human and animal noninfectious diseases: etiology, mechanisms, diagnosis and treatment of diseases, poisonings and injuries (without neurological diseases)
Host institution
Uniwersytet Wrocławski, Wydział Biotechnologii
Voivodeship: dolnośląskie
Principal investigator (from the host institution)
Number of co-investigators in the project: 3
Call
SONATA 16 – announced on 2020-09-15
- Amount awarded
- 996 400 PLN
- Project start date
- 2021-07-02
- Project end date
- 2026-01-01
- Project duration
- 54 months (the same as in the proposal)
- Project status
- Project completed
Project description
Download the project description in a pdf file
Note — project descriptions were prepared by the authors of the applications themselves and placed in the system in an unchanged form.
Information in the final report
Publication in academic press/journals (1)
-
Characterization of two melanoma cell lines resistant to BRAF/MEK inhibitors (vemurafenib and cobimetinib)
- Authors:
- Kot M, Simiczyjew A, Wądzyńska J, Ziętek M, Matkowski R, Nowak D.
- Academic press:
- Cell Communication and Signaling (year: 2024, volume: 22, pages: 410), Publisher: Springer Nature
- Status:
- Published
- DOI:
- 10.1186/s12964-024-01788-3 – link to the publication